JP2017515841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515841A5 JP2017515841A5 JP2016567413A JP2016567413A JP2017515841A5 JP 2017515841 A5 JP2017515841 A5 JP 2017515841A5 JP 2016567413 A JP2016567413 A JP 2016567413A JP 2016567413 A JP2016567413 A JP 2016567413A JP 2017515841 A5 JP2017515841 A5 JP 2017515841A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- taa
- antagonist
- immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020072789A JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992771P | 2014-05-13 | 2014-05-13 | |
| US61/992,771 | 2014-05-13 | ||
| PCT/US2015/029885 WO2015175340A1 (en) | 2014-05-13 | 2015-05-08 | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072789A Division JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017515841A JP2017515841A (ja) | 2017-06-15 |
| JP2017515841A5 true JP2017515841A5 (enExample) | 2018-06-07 |
Family
ID=53264790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567413A Pending JP2017515841A (ja) | 2014-05-13 | 2015-05-08 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
| JP2020072789A Active JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020072789A Active JP7368305B2 (ja) | 2014-05-13 | 2020-04-15 | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3142689B1 (enExample) |
| JP (2) | JP2017515841A (enExample) |
| AU (1) | AU2015259516B2 (enExample) |
| CA (1) | CA2946606C (enExample) |
| DK (1) | DK3142689T3 (enExample) |
| ES (1) | ES2851451T3 (enExample) |
| IL (1) | IL248511B (enExample) |
| WO (1) | WO2015175340A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11701418B2 (en) | 2015-01-12 | 2023-07-18 | Geovax, Inc. | Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40) |
| US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| WO2017120577A1 (en) | 2016-01-08 | 2017-07-13 | Geovax Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| WO2017136419A1 (en) | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
| CN107281474A (zh) * | 2016-04-11 | 2017-10-24 | 中国科学院上海巴斯德研究所 | 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物 |
| PH12018502112B1 (en) | 2016-04-12 | 2024-03-27 | Servier Lab | Anti-tim-3 antibodies and compositions |
| EP4253419A3 (en) | 2016-06-02 | 2024-05-22 | Ultimovacs ASA | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| CN109757103B (zh) | 2016-07-14 | 2024-01-02 | 百时美施贵宝公司 | 针对tim3的抗体及其用途 |
| US20190381157A1 (en) * | 2017-01-29 | 2019-12-19 | Zequn Tang | Methods of immune modulation against foreign and/or auto antigens |
| UA129904C2 (uk) * | 2017-04-05 | 2025-09-10 | Ле Лаборатуар Сервьє | Комбінація антитіла до tim-3 й антитіла до pd-1 для лікування раку |
| CA3062549A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| ES2965352T3 (es) | 2017-05-30 | 2024-04-12 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3) |
| WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | PERSONALIZED VACCINE |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| CN111918660A (zh) * | 2018-01-24 | 2020-11-10 | 复诺健生物科技加拿大有限公司 | 重组病毒疫苗 |
| CN111253485A (zh) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | 抗人tim-3单克隆抗体及其应用 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| EP4164682A1 (en) * | 2020-06-10 | 2023-04-19 | Bavarian Nordic A/S | A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| KR20230093282A (ko) | 2020-10-23 | 2023-06-27 | 브리스톨-마이어스 스큅 컴퍼니 | 폐암에 대한 lag-3 길항제 요법 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1820858B1 (en) | 1991-03-01 | 2009-08-12 | Dyax Corporation | Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof |
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| DE69435171D1 (de) | 1993-09-14 | 2009-01-08 | Pharmexa Inc | Pan dr-bindeproteinen zur erhöhung der immunantwort |
| US6165460A (en) | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
| AU731860B2 (en) | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| CA2282300C (en) | 1997-02-24 | 2011-08-02 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
| SK4272001A3 (en) | 1998-10-05 | 2003-02-04 | Pharmexa As | Methods for therapeutic vaccination |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| DE60235041D1 (de) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | Und ihre verwendung |
| WO2005046622A2 (en) * | 2003-11-12 | 2005-05-26 | Therion Biologics Corporation | Custom vectors for treating and preventing pancreatic cancer |
| KR20070037570A (ko) * | 2004-03-24 | 2007-04-05 | 텔로스 파마슈티칼스 인코포레이티드 | 백신에 대한 면역반응을 향상시키는 보강제로서의 조성물및 이의 사용 방법 |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| WO2009097394A2 (en) * | 2008-01-29 | 2009-08-06 | The Brigham And Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
| EP2482849B1 (en) | 2009-09-30 | 2018-06-06 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| JP5760796B2 (ja) | 2011-07-22 | 2015-08-12 | 富士通株式会社 | 冷却ユニット |
| IN2014KN00920A (enExample) | 2012-06-21 | 2015-10-09 | Compugen Ltd | |
| EP2908851A1 (en) * | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
-
2015
- 2015-05-08 ES ES15724454T patent/ES2851451T3/es active Active
- 2015-05-08 JP JP2016567413A patent/JP2017515841A/ja active Pending
- 2015-05-08 WO PCT/US2015/029885 patent/WO2015175340A1/en not_active Ceased
- 2015-05-08 EP EP15724454.2A patent/EP3142689B1/en active Active
- 2015-05-08 CA CA2946606A patent/CA2946606C/en active Active
- 2015-05-08 DK DK15724454.2T patent/DK3142689T3/da active
- 2015-05-08 AU AU2015259516A patent/AU2015259516B2/en active Active
- 2015-05-08 IL IL248511A patent/IL248511B/en unknown
-
2020
- 2020-04-15 JP JP2020072789A patent/JP7368305B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515841A5 (enExample) | ||
| JP2017515837A5 (enExample) | ||
| JP2016537417A5 (enExample) | ||
| DeMaria et al. | Cancer vaccines | |
| JP7368305B2 (ja) | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 | |
| RU2016148311A (ru) | Комбинированная терапия для лечения рака с помощью рекомбинантного поксвируса, экспрессирующего опухолевый антиген, и антагониста или агониста молекулы иммунной контрольной точки | |
| RU2016122035A (ru) | Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки | |
| Madan et al. | Clinical evaluation of TRICOM vector therapeutic cancer vaccines | |
| JP2022507744A5 (enExample) | ||
| ES2617983T3 (es) | Terapia de combinación que incluye anticuerpos de unión a antígenos asociados a tumores | |
| JP2018522822A5 (enExample) | ||
| Milani et al. | Recent advances in the development of breast cancer vaccines | |
| EP2596801A1 (en) | Methods for treating cancer with mva | |
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| JP2023503857A5 (enExample) | ||
| Haldar et al. | Worth a pound of cure? Emerging strategies and challenges in cancer immunoprevention | |
| CN119770632A (zh) | 诱导免疫应答的组合物和方法 | |
| Kraynyak et al. | Tapping the potential of DNA delivery with electroporation for cancer immunotherapy | |
| JP6297641B2 (ja) | 愛玩動物の癌の補助治療としてのＨｅｒ２ＤＮＡワクチン | |
| JP2018531238A (ja) | 抗腫瘍性組成物 | |
| US20180028630A1 (en) | Compositions and methods for therapeutic anti-cancer vaccination | |
| Plunkett et al. | Immunotherapy: the last 25 years | |
| Witt | Cripto-1: potential target for cancer immunotherapy?! | |
| Manne et al. | Immunotherapy and targeted therapies for colorectal liver metastasis | |
| JP2017531699A5 (enExample) |